Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma

The study is to observe safety, survival effect and peripheral T-lymphocyte subsets of combination therapy with percutaneous microwave ablation (MWA) and adoptive immunotherapy in hepatocellular carcinoma(HCC).

Trial Details

NCT ID
NCT02851784
Phase
PHASE2 / PHASE3
Sponsor
Chinese PLA General Hospital
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • adoptive immunotherapy
  • MWA
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • single HCC of 5 cm or smaller;
  • three or fewer multiple HCC with a maximum dimension of 3 cm or less;
  • absence of portal vein thrombosis or extrahepatic metastases;
  • Child-Pugh classification A or B;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →